logo

For the Inventor, By the Inventor

Boston, MA, United States of America

Huilei Xu

This inventor holds 7 USPTO granted patents and 5 published patent applications and 1 EPO patent. Top assignee: Alnylam Pharmaceuticals, Inc.. Active years: 2019-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Huilei Xu. Retrieved from https://idiyas.com/inventor/huilei-xu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 7 

% Patents Active = 85.7

 

Average Co-Inventor Count = 3.6

ph-index = 1

Forward Citations = 5(Granted Patents)


Location History:

  • Boston, MA (US) (2019 - 2022)
  • Cambridge, MA (US) (2024)

Company Filing History:

goldMedal7 out of 466 
 
Alnylam Pharmaceuticals, Inc.
 patents

Years Active: 2019-2026

Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents
1. 12577564 - Sterol regulatory element binding protein (SREBP) chaperone (SCAP) iRNA compositions and methods of use thereof (2026-03-17),
2. 11987792 - Compositions and methods for inhibiting expression of the LECT2 gene (2024-05-21),
3. 11434487 - Sterol regulatory element binding protein (SREBP) chaperone (SCAP) iRNA compositions and methods of use thereof (2022-09-06),
4. 11066670 - Insulin-like growth factor binding protein, acid labile subunit (IGFALS) and insulin-like growth factor 1 (IGF-1) iRNA compositions and methods of use thereof (2021-07-20),
5. 10767177 - Sterol regulatory element binding protein (SREBP) chaperone (SCAP) iRNA compositions and methods of use thereof (2020-09-08),
6. 10640770 - Hepatitis D virus (HDV) iRNA compositions and methods of use thereof (2020-05-05),
7. 10494632 - Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof (2019-12-03),

Title: The Innovative Contributions of Huilei Xu

Introduction

Huilei Xu is a prominent inventor based in Boston, MA, known for his significant contributions to the field of biotechnology. With a total of six patents to his name, Xu has made remarkable strides in developing innovative solutions for genetic expression and related disorders.

Latest Patents

Among his latest patents, Xu has developed compositions and methods for inhibiting the expression of the LECT2 gene. This invention involves double-stranded ribonucleic acid (dsRNA) compositions that target the LECT2 gene, providing methods to alter its expression. Another notable patent focuses on sterol regulatory element binding protein (SREBP) chaperone (SCAP) iRNA compositions. This invention relates to dsRNAi agents and compositions that target the SCAP gene, offering methods to inhibit its expression and treat disorders such as nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).

Career Highlights

Huilei Xu is currently employed at Alnylam Pharmaceuticals, Inc., where he continues to push the boundaries of genetic research and therapeutic development. His work has been instrumental in advancing the understanding of gene regulation and its implications for various health conditions.

Collaborations

Xu collaborates with notable colleagues, including Gregory Hinkle and Kevin Fitzgerald, who contribute to the innovative environment at Alnylam Pharmaceuticals. Their combined expertise fosters a culture of creativity and scientific advancement.

Conclusion

Huilei Xu's contributions to biotechnology through his patents and collaborative efforts highlight his role as a leading inventor in the field. His work not only addresses critical health issues but also paves the way for future innovations in genetic therapies.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…